Indian Pharmas Now Dominate Country’s Market In Wake Of Patent Reforms (India)
This article was originally published in PharmAsia News
Indian pharmaceutical makers need not have been concerned about patent reforms allowing multinational companies to dominate the Indian market. India-based drug makers appear to have staved off that competition during the three years since reform by beginning to make their own patented products. Before the intellectual property changes were made to comply with World Trade Organization demands, U.K.-based GlaxoSmithKline had the highest market share in India, but that has dropped to third place behind Cipla and Ranbaxy Laboratories. Some experts caution three years of experience under the new laws are not long enough to know the real impact. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.